15162 - ISTH "Thromboembolism in Cancer Patients"

Biological Mechanisms Involved in Cancer Coagulopathy – Janusz Rak
The presentation will review some of the biological mechanisms linking thrombosis to cancer progression, including the role of tumour-associated vascular anomalies, systemic nature of the advanced disease and the impact of oncogenic mutations on the coagulant phenotype of cancer cells. Experimental evidence will also be considered in relation to the possible involvement of the coagulation system effectors, especially tissue factor, in the biology cancer cells, including events surrounding tumour initiation, angiogenic switch, inflammatory responses and their therapeutic implications.

Prevention and Treatment – Alok Khorana
Overview of approaches to prevention including identifying patients at high risk for venous thromboembolism. The talk will also cover and best practices in treatment of cancer-associated thrombosis

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
 
Designation of Credit Statement:
The Medical College of Wisconsin designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Please note: The course fee is $25.00 in addition to a $2.50 processing fee which is assessed for all electronic registrations.
 
More information and online registration:  http://www.prolibraries.com/isth/
 
 

 

Target Audience

Clinicians and trainees who are interested in the biological mechanisms linking cancer and thrombosis and how to prevent and treat thrombosis in cancer patients.  Researchers and non-medical trainees with an interest in the vascular abnormalities in cancer would also be interested in the presentation.

 

Learning Objectives

At the conclusion of this activity, I will be able to:

  • To consider the convergence of vascular, blood-related and tumour-related events underlying thrombosis in cancer patients.
  • To appreciate the complexity and disease-specific aspects amongst processes occurring at the tumour-vascular interface which contribute to coagulation system activation in cancer.
  • To discuss the possible impact of coagulation system activation on the biology of cancer cells.
  • To understand the link between oncogenic driver events and their related changes in the molecular repertoire of coagulant effector genes (coagulome) in specific cancer subtypes.
  • To highlight coagulopathy as a systemic manifestation of the malignant process and a step in the continuum of coordinated biological responses, including inflammation, angiogenesis and tissue repair programs.
  • Understand risk assessment for cancer-associated thrombosis
  • Identify appropriate strategies for thromboprophylaxis
  • Outline best treatments of cancer-associated thrombosis
Additional information

CME Coordinator Contact Information

Name: 
Cary Clark
Phone Number: 
+1 (919) 929-3807
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
07/29/2015
Course expires: 
07/29/2016
Cost:
$2.50
Planning Committee:
Yukio Ozaki
Geoff Barnes
Chris Ward
Cary Clark
Stephen Watson
 
Speakers:
 
  Alok A. Khorana, MD
 
 Janusz Rak, MD, PhD
 
 Moderator, Chris Ward
 
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:  
 

Name

Company

Role

Chris Ward, MD

Bayer

Advisory Board, Speaker

Pfizer, BMS

Advisory Board, Speaker

Boehringer-Ingelheim

Advisory Board, Speaker

Alexion

Advisory Board

Medimark

Steering Committee Member, Speaker

Geoff Barnes

BMS, Pfizer, Blue Cross Blue Shield of Michigan

Primary Investigator & Co-Investigator

Yukio Ozaki

Sysmex

Advisory Board

Janusz RakNX PharmaGenIntellectual Property
Alok KhoranaLeoSteering Committee
 JanssenSteering Committee
 PfizerConsulting


In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Accreditation Period

Course opens: 
07/29/2015
Course expires: 
07/29/2016

Price

Cost:
$2.50
Please login or register to take this course.

Required Hardware/software

To view the webcast on your computer go to https://www.isth.org/  click the Events/Webinars tab and view the ISTH 2015 Archived Webinars

Participant Privacy